U.S. research institution creates biotech joint venture at Mariel

Source : Johannes Werner Wed Sep 26, 03:35 pm EST
While the small Roswell Park biotech joint venture is neither the first U.S. venture at Mariel, and commercialization of the drug is — at best — years and hundreds of millions of dollars worth of testing away, its creation is significant. Innovative Immunotherapy Alliance S.A. is not only the first U.S.-Cuban biotech joint venture, but it is taking shape amid tightening U.S. sanctions. Previous Top Stories
Thumb

Data & Maps

Previous entries
Cuba Standard.com Cuba News.com

ABOUT US | CONTACT US | PRIVACY POLICY
Copyright Cuba Standard